Pharmacological therapy for cerebral cavernous malformations.

COI Statement

RA-SS declares funding paid to The University of Edinburgh from the British Heart Foundation, the Chief Scientist Office of the Scottish Government, Recursion Pharmaceuticals, European Stroke Organisation, Novo Nordisk, and the UK Clinical Research Collaboration network of registered Clinical Trials Units. MJT declares no competing interests.